Wall Street brokerages expect that Polarityte Inc (NASDAQ:PTE) will post sales of $1.40 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Polarityte’s earnings, with the highest sales estimate coming in at $1.80 million and the lowest estimate coming in at $1.00 million. Polarityte reported sales of $10,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 13,900%. The business is expected to issue its next quarterly earnings results on Monday, April 22nd.
According to Zacks, analysts expect that Polarityte will report full year sales of $15.34 million for the current year, with estimates ranging from $8.40 million to $20.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $44.57 million, with estimates ranging from $30.20 million to $55.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Polarityte.
Polarityte (NASDAQ:PTE) last posted its quarterly earnings data on Monday, January 14th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.06. Polarityte had a negative net margin of 4,259.44% and a negative return on equity of 258.52%. The firm had revenue of $1.13 million for the quarter, compared to analyst estimates of $0.80 million.
An institutional investor recently bought a new position in Polarityte stock. Comprehensive Portfolio Management LLC bought a new stake in Polarityte Inc (NASDAQ:PTE) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 21,702 shares of the company’s stock, valued at approximately $232,000. Comprehensive Portfolio Management LLC owned about 0.10% of Polarityte at the end of the most recent quarter. Institutional investors and hedge funds own 54.85% of the company’s stock.
Shares of NASDAQ PTE traded down $0.26 during trading on Wednesday, hitting $8.18. 468,505 shares of the company were exchanged, compared to its average volume of 349,539. The firm has a market capitalization of $186.44 million, a P/E ratio of -1.68 and a beta of 1.48. Polarityte has a 1 year low of $7.93 and a 1 year high of $41.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 13.76 and a current ratio of 13.80.
PolarityTE, Inc, a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services.
Recommended Story: What is an Initial Public Offering (IPO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Polarityte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarityte and related companies with MarketBeat.com's FREE daily email newsletter.